We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.34%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.32B
AUM Growth
+$623M
(+13%)
Cap. Flow
+$473M
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
31.02%
Holding
1,563
New
308
Increased
332
Reduced
859
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$43.7M |
| 2 |
American Tower
AMT
|
+$34.7M |
| 3 |
Crown Castle
CCI
|
+$21.3M |
| 4 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$19.1M |
| 5 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$80.9M |
| 2 |
Microsoft
MSFT
|
+$63.9M |
| 3 |
Amazon
AMZN
|
+$61.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$26.4M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$24.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.33% |
| 2 | Technology | 16.44% |
| 3 | Consumer Discretionary | 8.8% |
| 4 | Healthcare | 7.69% |
| 5 | Communication Services | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Genesis Energy
GEL
$1.81B
| $40K | ﹤0.01% |
6,365
-808
| -11% | -$4.59K |
|
|
ALBO
1302
DELISTED
Albireo Pharma Inc
ALBO
| $40K | ﹤0.01% |
+1,069
| New | +$38.9K |
|
1303
Protagonist Therapeutics
PTGX
$8.8B
| $39K | ﹤0.01% |
+1,958
| New | +$42.1K |
|
1304
ALX Oncology
ALXO
$268M
| $38K | ﹤0.01% |
+446
| New | +$26.8K |
|
|
YMAB
1305
DELISTED
Y-mAbs Therapeutics
YMAB
| $38K | ﹤0.01% |
764
-11
| -1% | -$509 |
|
|
HEP
1306
DELISTED
Holly Energy Partners, L.P.
HEP
| $38K | ﹤0.01% |
2,693
-72
| -3% | -$935 |
|
|
KLRS
1307
Kalaris Therapeutics
KLRS
$79.5M
| $37K | ﹤0.01% |
+41
| New | +$31.5K |
|
1308
Imperial Oil
IMO
$60.8B
| $36K | ﹤0.01% |
+1,898
| New | +$30.4K |
|
1309
Krystal Biotech
KRYS
$10.7B
| $36K | ﹤0.01% |
608
-240
| -28% | -$12K |
|
1310
Precigen
PGEN
$1.97B
| $36K | ﹤0.01% |
+3,506
| New | +$22.7K |
|
1311
AnaptysBio
ANAB
$1.54B
| $35K | ﹤0.01% |
1,612
-250
| -13% | -$6.07K |
|
1312
Black Diamond Therapeutics
BDTX
$101M
| $35K | ﹤0.01% |
+1,093
| New | +$35.9K |
|
1313
Puma Biotechnology
PBYI
$406M
| $35K | ﹤0.01% |
3,435
-1,954
| -36% | -$19.8K |
|
|
MANT
1314
DELISTED
Mantech International Corp
MANT
| $35K | ﹤0.01% |
395
+23
| +6% | +$1.74K |
|
1315
Gossamer Bio
GOSS
$100M
| $34K | ﹤0.01% |
3,553
+1,705
| +92% | +$16.8K |
|
1316
MannKind Corp
MNKD
$1.21B
| $34K | ﹤0.01% |
+10,728
| New | +$28.1K |
|
1317
Vaxcyte
PCVX
$7.88B
| $34K | ﹤0.01% |
+1,272
| New | +$47.3K |
|
|
VIE
1318
DELISTED
Viela Bio, Inc. Common Stock
VIE
| $34K | ﹤0.01% |
932
+380
| +69% | +$13.3K |
|
1319
CEMIG Preferred Shares
CIG
$6.21B
| $33K | ﹤0.01% |
21,464
+14,941
| +229% | +$18.2K |
|
|
TCRR
1320
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $33K | ﹤0.01% |
+1,081
| New | +$27.3K |
|
|
AKRO
1321
DELISTED
Akero Therapeutics
AKRO
| $32K | ﹤0.01% |
+1,250
| New | +$34.8K |
|
1322
Nkarta
NKTX
$159M
| $32K | ﹤0.01% |
+515
| New | +$21.4K |
|
1323
V2X
VVX
$2.82B
| $32K | ﹤0.01% |
641
| – | – |
|
1324
Quince Therapeutics
QNCX
$18.9M
| $31K | ﹤0.01% |
+6
| New | +$53.2K |
|
1325
Arcutis Biotherapeutics
ARQT
$3.55B
| $30K | ﹤0.01% |
+1,071
| New | +$26.2K |
|
Similar funds
SAM
Pacer Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Pacer Advisors held 1,563 positions worth $5.32B, up 13% from $4.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pacer Advisors deployed $473M of net new capital in Q4 2020, opening 308 new positions and adding to 332 existing holdings. Its largest new stake was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $80.9M trimmed.
- Pacer Advisors's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
- Pacer Advisors added most to Equinix in Q4 2020, an estimated $43.7M increase.
- Pacer Advisors's biggest Q4 2020 reduction was Apple, cutting an estimated $80.9M.
- Pacer Advisors fully exited INDUS Realty Trust, Inc. (MD) Common Stock in Q4 2020, selling an estimated $1.83M.
- Pacer Advisors's ten largest holdings make up 31% of its $5.32B portfolio in Q4 2020.
- Pacer Advisors opened 308 new positions and closed 60 in Q4 2020.
- Pacer Advisors's portfolio value rose 13% quarter-over-quarter to $5.32B.
Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.